BioWorld

March 23, 2009

Poniard's Pipeline Narrows to Picoplatin After Cost Cutting

Poniard Pharmaceuticals Inc. is cutting 12 percent of its staff and discontinuing in-house preclinical research operations, the latest in a recent spate of layoffs. (BioWorld Today) Read More

HHS, IOM Take First Steps on Comparative Effectiveness

'Endogenous Lithium' Found to Play Role in Schizophrenia

NewCo News: Otonomy Tackles Hearing and Balance Disorders with Delivery

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...